| Catalog No. | HB038016 |
|---|
| Species reactivity | Human |
|---|
| Applications | Research Grade Biosimilar |
|---|
| Host species | Chimeric |
|---|
| Isotype | IgG1-kappa |
|---|
| Expression system | Mammalian Cells |
|---|
| Clonality | Monoclonal |
|---|
| Target | CD30L receptor, Ki-1 antigen, CD30, TNFRSF8, D1S166E, Tumor necrosis factor receptor superfamily member 8, Lymphocyte activation antigen CD30 |
|---|
| Concentration | 1mg/ml |
|---|
| Endotoxin level | Please contact the lab for this information. |
|---|
| Purity | >95% purity as determined by SDS-PAGE. |
|---|
| Purification | Protein A/G, purified from cell culture supernatant. |
|---|
| Accession | P28908 |
|---|
| Form | Liquid |
|---|
| Storage buffer | 0.01M PBS,pH7.4. |
|---|
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -571°C. |
|---|
| Alternate Names | SGN-35,cAC10-Val-Cit-MMAE,CAS:914088-09-8,2088770-90-3 |
|---|
| Background | Brentuximab is a monoclonal antibody targeting CD30. Brentuximab is conjugated with monomethyl auristatin E (MMAE) (HY-15162) to form the antibody-drug conjugate Brentuximab vedotin (HY-P99107), which can induce apoptosis in primary effusion lymphoma cells. Brentuximab vedotin exhibits antitumor activity with an IC50 of 10 nM against human CD30+ cancer cells. |
|---|
| Note | For research use only. Not for use in clinical or therapeutic applications. |
|---|
